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Aim. Self-expanding metal stents (SEMSs) are increasingly used for the palliation of metastatic colorectal cancer and as a bridge
to surgery for obstructing tumours. This case series analyses the learning curve and changes in practice of colorectal stenting over
a three year period. Methods. A study of 40 patients who underwent placement of SEMS for the management of colorectal cancer.
Patients spanned the learning curve of a single surgeon endoscopist. Results. Technical success rates increased from 82% initially,
using an average of 1.7 stents per procedure, to a 94% success rate where all patients were stented using a single stent. There has
been a change in practice from elective palliative stenting toward emergency preoperative stenting. Conclusion. There is a steep
learning curve for the use of SEMS in the management of malignant colorectal bowel obstruction. We suggest that at least 20 cases
are required for an operator to be considered experienced.
1.Introduction
Up to 29% of the 40000 new diagnoses of colorectal cancer
each year in the UK present with obstructive symptoms [1,
2]. Self-expanding metal stents (SEMSs) are being used with
increasing success for the palliation of metastatic colorectal
cancer and as a bridge to surgery for obstructing tumours
despite the absence of high level evidence for their safety and
eﬃcacy. With the advent of the ColoRectal Stenting Trial
(CReST trial), a multicentred RCT, there has been debate
as to the learning curve for colorectal stenting. This case
series investigated the ﬁrst three years of a single surgeon
endoscopist stenting experience analysing the change in
practice over time and the learning curve.
2. Patientsand Methods
Data was collected prospectively on 40 patients presenting
with acute or subacute large bowel obstruction that subse-
quently underwent the insertion of an SEMS. There were
2 indications for insertions of an SEMS in this case series.
Firstly, patients with disseminated malignancy from a lesion
in the left colon who were experiencing obstructing symp-
toms were considered. The decision to attempt insertion of
SMES was taken in the MDT. These cases with subacute
large bowel obstruction were stented for palliation only.
The second indication for stenting was acute left-sided large
bowel obstruction. Stenting was indicated in this cohort
if the patient was at high risk for emergency surgery or
had disseminated disease. Consecutive eligible patients were
selected over a three-year period (2006–2008).
The procedures were performed by a single surgeon
endoscopist and a consultant radiographer in one cen-
tre. Stents were performed under combined endoscopic
and radiological guidance (Figure 1). Technical success was
deﬁned as successful placement of the SEMS across the
obstructing lesion with good passage of contrast post
stenting. In this series, technical success equated to clinical
success and all patients who achieved a technical success had
symptomatic relief.
Threepatientswereexcludedatthetimeoftheprocedure
as stenting was thought inappropriate (stenting was not
attempted). One patient had a pre-existing perforation
demonstrated with contrast and preceded with operative
intervention. Endoscopy and radiological studies failed to2 International Journal of Surgical Oncology
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Figure 1: A series of images demonstrating the stages involved in endoscopically guided colorectal stenting. (a) The tumour is directly
visualised with the endoscope, and the guide wire is passed through the end of the scope. (b) The deployment system is passed through the
stricture. (c) The stent has been successfully deployed. The stent boundaries can be clearly identiﬁed.
detect an obstructing malignant lesion in the other two
patients, and stenting was not performed.
This paper analysed the resulting 37-patient case series.
To aid with analysis and to show a change in practice over
time, the series was divided chronologically in half (1st 18
patient were stented in 2006 and 2nd 19 patients stented
in 2007 and 2008). The site of the lesions stented were
6 descending colon, 9 sigmoid colon, 12 rectosigmoid, 8
rectum, 1 extrinsic compression, and 1 at the splenic ﬂexure.
3. Results
Thirty seven patients underwent stent placement (22 male,
15 Female) with an average age of 74 (55–95). 18 (49%)
patients presented as an emergency with acute large bowel
obstruction. Of these patients, the staging investigation
demonstrated disseminated disease in 11 cases. After discus-
sionintheMDTallthesepatientweresubsequentlymanaged
palliatively (nonoperatively). The remaining 7 had localised
disease and were stented as a bridge to surgery. The other 19
patientspresentedwithsubacutebowelobstructionandwere
electively stented. All of these patients were later managed
with palliation for disseminated disease. Over 80% of the
patients in this series were managed with palliation. As a
result of this they did not undergo surgical resection and
formal histological (TNM) staging.
Thesiteoflesionandstentingvaried:6descendingcolon,
9 sigmoid colon, 12 rectosigmoid, 8 rectum, 1 extrinsic
compression, and 1 at the splenic ﬂexure. Complications
included 4 failures (11%), 4 tumour overgrowths (11%), and
1 stent migration (3%). Three of the tumour overgrowth
cases were restented at day 22, 130, and 146 after the original
procedure. One patient had a late tumour overgrowth which
wasmanagedwithadefunctioningloopileostomy.Therewas
1earlyperforationand1late(2weeks)perforationin2ofthe
patients that were restented. Both these patients died as they
were not ﬁt for surgery.
Figure 2 demonstrates the diﬀerence between the
patients in the ﬁrst and second half of the case series.International Journal of Surgical Oncology 3
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Figure 2: A comparison between the ﬁrst and second half of the
case series showing the change in practice over time.
Table 1: The learning curve for SEMS.
Stenting group Percentage success
(%)
N◦ of stents per
procedure
1–11 82 1.7
12–21 90 1.1
22–37 94 1.0
The early patients were predominantly palliative patients
electively admitted with subacute large bowel obstruction.
67% in the ﬁrst 18 patients and 37% in the subsequent 19
patients were electively stented for this indication. In the
second half of the series, more SEMS are deployed acutely
as a bridge to surgery or to palliate emergency large bowel
obstruction. Of the ﬁrst 18 patients only 11% of patients
were stented following emergency presentation with acute
large bowel obstruction, in comparison to 26% in the
subsequent 19 patients.
The ﬁrst 11 stents performed had an 82% technical
s u c c e s sr a t ea n dr e q u i r e da na v e r a g eo f1 . 7s t e n t sp e r
procedure. The subsequent 10 stents performed had a 90%
technical success rate and required average of 1.1 stents
per procedure. The ﬁnal 16 stents performed had a 94%
technical success rate. All of these patients were stented using
a single stent. This is shown in Table 1 demonstrating how
technical success increased and number of stents decreased
with experience.
4. Discussion
Colorectal cancer commonly presents with large bowel
obstruction, often at an advanced stage with only 50%
of patients being suitable candidates for curative surgery.
Emergency surgery in these patients has a high mortality
and morbidity when compared to elective surgery. Over
time, several techniques such as balloon dilatation and laser
ablation have been attempted with the aim of decompressing
the bowel. These techniques had limited success. The use of
stents in colorectal obstruction was ﬁrst reported in the early
1990s [3, 4] and subsequently has been used to avoid surgery
in patients with metastatic disease and as a bridge to surgery
in those with localised disease.
SEMS have many advantages for patients with acute
bowel obstruction. An SEMS can be used to control an
emergency presentation allowing patient optimisation. A
study of 8000 patients found that emergency surgery has a
mortalityof19.3%comparedto5.6%forelectivesurgery[5].
Elective surgery also reduces morbidity, with higher rates of
primaryanastomosisandlowerratesofseverecomplications.
Martinez-Santos et al. found that patients undergoing emer-
gency surgery for acute malignant large bowel obstruction
had a primary anastomosis rate of 41% compared with 87%
in patients operated on following insertion of an SEMS [6],
thus saving a signiﬁcant amount of stoma-related morbidity.
In the long term, only 60% of patients with a colostomy pro-
ceedtostomareversal[7].Inpatientshavingcurativesurgery
following a bridge to surgery SEMS, up to 95% go onto
having a single staged procedure avoiding a colostomy [8].
There are also health economic advantages [8]w i t h
reduced hospital stay [9, 10] and length of time in critical
carebeds[6,11].Importantly,stentingcanbuytimeforstag-
ing, treatment planning, neoadjuvant therapies and patient
optimisation. In this case series 18 patients presented with
acute bowel obstruction and underwent emergency stenting.
Of these patients, 11 (61%) were found to have disseminated
disease at staging and hence avoided unnecessary major
surgery.
Colorectal stenting itself has disadvantages. The majority
ofthepublishedliteratureislimitedbyhavingasmallsample
size and being nonrandomised; consequently there is a large
range in quoted complication rates. A review by Watt et al.
found median complication rates of stent migration 11%,
perforation 4.5%, and tumour overgrowth 12% [12]. Clini-
calsuccessisusuallyquotedatarateof85–100%[1,8,12,13]
with mortality between 0 and 2%. This study had a primary
perforation rate of 0% in line with the literature, but we had
an overall mortality of 2/37 (5%) when restented patients
were taken into account. Successful treatment of acute left-
sided colorectal obstruction depends on a number of opera-
torandpatientfactors.ACochranereviewin2002concluded
that the limited number of randomised control trials into the
management of obstructing left-sided colorectal carcinoma
together with methodological weaknesses does not allow
reliable assessment of the best treatment strategy [14]. There
is a clear need for further large randomised studies.
The only prospective multicentred RCT to date, the
Stent-in 1 study [15, 16], was stopped early following a high
rate of stent-related complications. In the proposed followup
Stent-in 2 study [17], it is suggested that SEMS should be
placed by an experienced gastroenterologist. They deﬁned
an experienced gastroenterologist as one who has placed
20 enteral stents of which at least 10 were colonic, without
giving evidence why these ﬁgures have been suggested.
This study found that there was a deﬁnite learning curve
for the insertion of SEMS, the ﬁrst 11 stents having only
an 82% success rate, the next 10 having a 90% success
rate, and the subsequent SEMS having a 94% success rate.
In this case series, it was also noted that the number of SEMS4 International Journal of Surgical Oncology
required to relieve an obstruction decreased with experience.
Initially an average of 1.7 stents were used per successful
procedure whereas towards the end of the series strictures
were consistently requiring only one stent. This increased
stent usage early in the series reﬂected inexperience and
technical diﬃculty rather than length of stricture. There was
no signiﬁcant diﬀerence between complications and length
of stricture between the groups. This evidence suggests that
operators should have a minimal experience of 20 colonic
SEMS to be eligible for inclusion in future RCTs.
Not being a randomised study, there is inevitable bias in
the selection of patient and treatment options. Experience
in colorectal stenting resulted in changes in practice over
time. As the study progressed, more stents were performed
on an emergency basis (33% of the ﬁrst 18 patients and
63% of the second 19 patients) in a patient demographic
who were likely to be more unwell. More stents were also
performed as a bridge to surgery in the second half of the
study (26% compared with 11%). This change in practice is
likely to reﬂect an increase in operator conﬁdence in their
technicalabilityandknowledgeofwhenstentingisandisnot
appropriate. The fact that the clinical success rates increased
along this learning curve despite more technically diﬃcult
patients suggests that there may also be a signiﬁcant learning
curve in patient selection.
There has also been a change in practice with regard
to restenting. The 2 mortalities in this series were patients
who died following the restenting of a multilevel obstruc-
tion. Both these patients required 2-3 stents to relieve the
obstruction caused by a long stricture, which in retrospect
was a mistake. If a reobstruction cannot be solved with a
single stent, practice has changed and a further stent would
not be attempted.
In conclusion this case series suggests that initially there
is a steep learning curve for the use of SEMS in the
management of malignant colorectal bowel obstruction of
about 11 cases. We suggest that at least twenty cases are
r e q u i r e df o ra no p e r a t o rt ob ec o n s i d e r e de x p e r i e n c e d .
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